WALTHAM, Mass., June 3, 2021 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:
SNDX), a clinical stage biopharmaceutical company developing an
innovative pipeline of cancer therapies, today announced that
members of its management team will participate in the Goldman
Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 2:10 p.m. ET.
A live webcast of the presentation can be accessed from the
Investor section of the Company's website at www.syndax.com, where
a replay of the event will also be available for a limited
time.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. The Company's pipeline includes SNDX-5613, a
highly selective inhibitor of the Menin–MLL binding interaction,
axatilimab, a monoclonal antibody that blocks the colony
stimulating factor 1 (CSF-1) receptor, and entinostat, a class I
HDAC inhibitor. For more information, please
visit www.syndax.com or follow the Company
on Twitter and LinkedIn.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
Ted Held
ted.held@gcihealth.com
Tel 212.798.9842
SNDX-G
View original
content:http://www.prnewswire.com/news-releases/syndax-announces-participation-in-goldman-sachs-42nd-annual-global-healthcare-conference-301304926.html
SOURCE Syndax Pharmaceuticals, Inc.